ArticleFrontiers in cell and developmental biology2021
CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer.
Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 1 synthesis or guideline pooled it, 158 citations in OpenAlex.
- EPSTI1 as an immune biomarker predicts the prognosis of patients with stage III colon cancer.Frontiers in immunology · 2022Pooled it
- CXCL11 recruits immunosuppressive cells to form a barrier at the invasive front of pancreatic cancer by activating the NF-κB/CCL2 axis.Translational oncology · 2026Article
- Inflammatory neuropathy in mouse and primate models of colorectal cancer.Nature communications · 2026Article
- Single-cell and deep learning identify hypoxia-responsive lncRNAs predicting outcomes in colorectal cancer.NPJ precision oncology · 2026Article
- ZBP1 Drives CD8+ T cell-mediated anti-tumor immunity in head and neck squamous cell carcinoma.PLoS genetics · 2026Article
- Shared Biomarkers LCN2 and CXCL11 for Ulcerative Colitis and Colon Cancer: Bioinformatics Analysis and Diagnostic Model Construction.Digestive diseases and sciences · 2026Article
- Identification of LILRB4 as a regulator of M2c macrophages and a potential immunotherapeutic target in ovarian cancer.Frontiers in immunology · 2026Article
- Expression, Prognostic Value, and Biological Function of CENPM in Colon Adenocarcinoma.Current medicinal chemistry · 2026Article
- RAB37 Exerts a Context-Dependent Role in Cutaneous Melanoma Progression by Promoting Tumor Cell Proliferation and Being Associated with Favorable Immune Characteristics.Cancer management and research · 2026Article
- Review
- Exploration of the diagnostic and therapeutic potential of the nucleocytoplasmic shuttling protein TMUB1 by inducing G0/G1 cell cycle arrest in ovarian cancer.Molecular & cellular oncology · 2026Article
- Construction of a novel prognostic model based on lncRNAs-related to DNA damage repair for predicting the prognosis of clear cell renal cell carcinoma.Annals of medicine · 2025Article
- Review
- Metabolic syndrome-related gene signature for prognosis and immune microenvironment prediction in hepatocellular carcinoma.Scientific reports · 2025Article
- A prognostic risk prediction model for gastric cancer based on the EFNA4 and ETS1 regulatory axis in tumor cells.Scientific reports · 2025Article
- A novel anoikis related gene prognostic model for colorectal cancer based on single cell sequencing and bulk transcriptome analyses.Scientific reports · 2025Article
- CXCL9 is a dual‑role biomarker in colorectal cancer linked to mitophagy and modulated by ALKBH5.Molecular medicine reports · 2025Article
- Murine cell lines with defined mutations model different histological subtypes of epithelial ovarian cancer.Disease models & mechanisms · 2025Article
- Identification of PD-L1-related biomarkers for selecting gastric adenocarcinoma patients for PD-1/PD-L1 inhibitor therapy.Discover oncology · 2025Article
- Serum Protein Profiling as theranostic biomarkers for Left- and Right-Sided Colon Cancer using LuminexCancer biomarkers : section A of Disease markers · 2025Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chemokine ligand C-X-C motif chemokine ligand 11 (CXCL11) is involved in the progression of various cancers, but its biological roles in colorectal cancer (CRC) remain confused. Therefore, the prognostic value and underlying mechanism of CXCL11 in CRC were preliminarily evaluated. Three independent datasets were used for mRNA-related analysis: one dataset from the Cancer Genome Atlas (TCGA,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.